SLC6A3 and major depressive disorder: This high heterogeneity was mainly due to the study by Wu et al. (2011), which had a ‘Poor’ overall quality rating on the Newcastle-Ottawa Scale, and demonstrated lower DAT availability in 13 patients with MDD relative to 10 controls with an effect size of 4.50 (Wu et al., 2011).